{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:04:03Z","timestamp":1795176243397,"version":"4.10.3"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Patient-Centered Clinical Research Coordinating Center"},{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HC21C0076"],"award-info":[{"award-number":["HC21C0076"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To develop a model for predicting flares after tapering the dose of tumour necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were obtained from the Korean College of Rheumatology Biologics and Targeted Therapy Registry. In total, 526 patients who received the standard-dose TNFi for at least 1\u2009year and tapered their dose were included in the derivation cohort. The main outcome was a flare occurrence defined as an Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) score of \u22652.1 after 1\u2009year of TNFi tapering. The final prediction model was validated using an independent cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 526 patients, 127 (24.1%) experienced flares. The final prediction model included negative human leucocyte antigen B27 (\u03b2\u2009=\u20091.088), inflammatory back pain (\u03b2\u2009=\u20091.072), psoriasis (\u03b2\u2009=\u20091.567), family history of SpA (\u03b2\u2009=\u20090.623), diabetes mellitus (\u03b2\u2009=\u20091.092), TNFi tapering by \u226550% of the standard-dose (\u03b2\u2009=\u20090.435), ASDAS-CRP at tapering (\u03b2\u2009=\u20091.029), and Bath Ankylosing Spondylitis Functional Index score at tapering (\u03b2\u2009=\u20090.194) as covariates. It showed an excellent discrimination performance (AUC\u2009=\u20090.828). According to the predictive risk, patients were classified into three groups (low-, intermediate- and high-risk). The probabilities of flares in these groups were 4.5%, 18.1% and 61.8%, respectively. The performance of the model in the validation cohort was also comparable.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The established prediction model accurately predicted the risk of flares after TNFi dose tapering in patients with axSpA using eight simple clinical parameters, which could be helpful to select appropriate patients for tapering their TNFi without flare in daily clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae138","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T01:12:56Z","timestamp":1710378776000},"page":"1155-1161","source":"Crossref","is-referenced-by-count":8,"title":["Flare prediction after tapering the dose of tumour necrosis factor inhibitors in patients with axial spondyloarthritis: a nationwide cohort study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7923-8729","authenticated-orcid":false,"given":"Jina","family":"Yeo","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center , Incheon,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Yeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital , Seoul,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Kyun","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital , Seoul,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kichul","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center , Seoul,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6975-8627","authenticated-orcid":false,"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital , Seoul,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-2276","authenticated-orcid":false,"given":"Tae-Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases , Seoul,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8624-2582","authenticated-orcid":false,"given":"Jun Won","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital , Seoul,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"2025030500183394000_keae138-B1","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"2025030500183394000_keae138-B2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2025030500183394000_keae138-B3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"2025030500183394000_keae138-B4","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025030500183394000_keae138-B5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025030500183394000_keae138-B6","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1007\/s10067-018-4290-0","article-title":"The effect of extra-articular manifestations on tumor necrosis factor-alpha inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry","volume":"37","author":"Kim","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025030500183394000_keae138-B7","first-page":"621","article-title":"Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population","volume":"19","author":"Schabert","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"2025030500183394000_keae138-B8","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"2025030500183394000_keae138-B9","first-page":"672","article-title":"The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab","volume":"29","author":"Heldmann","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2025030500183394000_keae138-B10","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10067-010-1542-z","article-title":"Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis","volume":"29","author":"Lee","year":"2010","journal-title":"Clin Rheumatol"},{"key":"2025030500183394000_keae138-B11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","article-title":"Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease","volume":"30","author":"Navarro-Compan","year":"2011","journal-title":"Clin Rheumatol"},{"key":"2025030500183394000_keae138-B12","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3899\/jrheum.141128","article-title":"Comparing tapering strategy to standard dosing regimen of tumor necrosis factor inhibitors in patients with spondyloarthritis in low disease activity","volume":"42","author":"Plasencia","year":"2015","journal-title":"J Rheumatol"},{"key":"2025030500183394000_keae138-B13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2014-205202","article-title":"A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study","volume":"75","author":"Zavada","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025030500183394000_keae138-B14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13075-019-1943-6","article-title":"Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025030500183394000_keae138-B15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025030500183394000_keae138-B16","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3899\/jrheum.141335","article-title":"Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial","volume":"42","author":"Yates","year":"2015","journal-title":"J Rheumatol"},{"key":"2025030500183394000_keae138-B17","first-page":"1","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biologics"},{"key":"2025030500183394000_keae138-B18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states","volume":"77","author":"Machado","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025030500183394000_keae138-B19","doi-asserted-by":"crossref","first-page":"b375","DOI":"10.1136\/bmj.b375","article-title":"Prognosis and prognostic research: what, why, and how?","volume":"338","author":"Moons","year":"2009","journal-title":"BMJ"},{"key":"2025030500183394000_keae138-B20","doi-asserted-by":"crossref","first-page":"1759720X20986732","DOI":"10.1177\/1759720X20986732","article-title":"Tumour necrosis factor inhibitor tapering in patients with ankylosing spondylitis at low disease activity: factors associated with flare","volume":"13","author":"Kwon","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025030500183394000_keae138-B21","first-page":"2398","article-title":"Tapering of TNF inhibitors in axial spondyloarthritis in routine care - 2-year clinical and MRI outcomes and predictors of successful tapering","volume":"61","author":"Wetterslev","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500183394000_keae138-B22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratacos","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025030500183394000_keae138-B23","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","article-title":"Predicting the outcome of ankylosing spondylitis therapy","volume":"70","author":"Vastesaeger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2025030500183394000_keae138-B24","doi-asserted-by":"crossref","first-page":"e000017","DOI":"10.1136\/rmdopen-2014-000017","article-title":"Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis","volume":"1","author":"Maneiro","year":"2015","journal-title":"Rmd Open"},{"key":"2025030500183394000_keae138-B25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/rheumatology\/kex457","article-title":"Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort","volume":"57","author":"Yahya","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500183394000_keae138-B26","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1093\/rheumatology\/keaa888","article-title":"The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis","volume":"60","author":"Provan","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500183394000_keae138-B27","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/art.40185","article-title":"Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia: results From a UK National Register","volume":"69","author":"Macfarlane","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025030500183394000_keae138-B28","doi-asserted-by":"crossref","first-page":"614255","DOI":"10.3389\/fimmu.2021.614255","article-title":"Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis","volume":"12","author":"McGonagle","year":"2021","journal-title":"Front Immunol"},{"key":"2025030500183394000_keae138-B29","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/annrheumdis-2018-213654","article-title":"Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?","volume":"78","author":"Siebert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025030500183394000_keae138-B30","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025030500183394000_keae138-B31","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1093\/rheumatology\/keab741","article-title":"Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study","volume":"61","author":"Michielsens","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500183394000_keae138-B32","doi-asserted-by":"crossref","first-page":"e14620","DOI":"10.1097\/MD.0000000000014620","article-title":"A quick decrease of bone marrow edema in sacroiliac joint could be served as a novel marker for dose tapering of etanercept in ankylosing spondylitis patients","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2025030500183394000_keae138-B33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ckj\/sfaa188","article-title":"External validation of prognostic models: what, why, how, when and where?","volume":"14","author":"Ramspek","year":"2020","journal-title":"Clin Kidney J"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae138\/57075880\/keae138.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1155\/57075880\/keae138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1155\/57075880\/keae138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:20:59Z","timestamp":1741134059000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/3\/1155\/7628321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,13]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae138","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,3,13]]}}}